Literature DB >> 10856171

Understanding drug allergies.

R Gruchalla1.   

Abstract

At this time, the incidence of adverse drug reactions can only be estimated because the intensive monitoring and documenting that is required to make this determination does not exist at most hospitals and clinics. Despite these limitations, a meta-analysis of prospective studies has estimated the incidence of serious adverse drug reactions in hospitalized patients to be 6.7% and the incidence of fatal adverse drug reactions to be 0.32%. When evaluating and managing the condition of a patient who has experienced an adverse drug reaction, the physician first obtains an accurate history and performs a careful physical examination to determine whether the reaction was immunologic in nature. Drug reactions that are immunologically mediated (1) require a period of sensitization, (2) occur in a small proportion of the population, (3) are elicited at drug doses far below the therapeutic range, and (4) subside after drug discontinuation in most instances. All possible culprit drugs should be identified, with dosages and dates of administration and discontinuation, and the patient should be asked about any previous drug exposure history. Although immunodiagnostic tests for allergic drug reactions are limited, several tests do exist and may be useful in the identification of drug-specific antibodies, drug-specific T lymphocytes, or mediators from activated cells. If the reaction was not consistent with an IgE-mediated event and if it did not involve serious organ damage, cautious rechallenge may be considered. For those reactions that appear to be IgE-mediated and for which there is no reliable skin test reagent, drug desensitization may be performed by allergists who are trained in this procedure.

Entities:  

Mesh:

Year:  2000        PMID: 10856171     DOI: 10.1067/mai.2000.106156

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  11 in total

1.  Retrospective Analysis of Pattern of Cutaneous Adverse Drug Reactions in Tertiary Hospital of Pauri Garhwal.

Authors:  Deepak Dimri; Rangeel Singh Raina; Swati Thapliyal; Vijay Thawani
Journal:  J Clin Diagn Res       Date:  2016-05-01

Review 2.  Preventing and managing drug-induced anaphylaxis.

Authors:  K L Drain; G W Volcheck
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

3.  Resistance evolution in HIV - modeling when to intervene.

Authors:  Liliana Mabel Peinado Cortes; Ryan Zurakowski
Journal:  Proc Am Control Conf       Date:  2012

4.  Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment.

Authors:  Alejandro Huerta-Saquero; Zahaed Evangelista-Martínez; Angélica Moreno-Enriquez; Ernesto Perez-Rueda
Journal:  Bioengineered       Date:  2012-08-16       Impact factor: 3.269

Review 5.  [Drug allergies. Clinical aspects, pathophysiology and treatment of cutaneous manifestations].

Authors:  B Sachs; H F Merk
Journal:  Hautarzt       Date:  2005-01       Impact factor: 1.198

Review 6.  Diagnosis and management of immediate hypersensitivity reactions to cephalosporins.

Authors:  Min-Hye Kim; Jong-Myung Lee
Journal:  Allergy Asthma Immunol Res       Date:  2014-10-15       Impact factor: 5.764

7.  Recent Advances in Severe Cutaneous Adverse Drug Reaction.

Authors:  Sudip Das; Abhishek De
Journal:  Indian J Dermatol       Date:  2018 Jan-Feb       Impact factor: 1.494

8.  Adverse cutaneous drug reaction.

Authors:  Surajit Nayak; Basanti Acharjya
Journal:  Indian J Dermatol       Date:  2008-01       Impact factor: 1.494

9.  The skin prick test - European standards.

Authors:  Lucie Heinzerling; Adriano Mari; Karl-Christian Bergmann; Megon Bresciani; Guido Burbach; Ulf Darsow; Stephen Durham; Wytske Fokkens; Mark Gjomarkaj; Tari Haahtela; Ana Todo Bom; Stefan Wöhrl; Howard Maibach; Richard Lockey
Journal:  Clin Transl Allergy       Date:  2013-02-01       Impact factor: 5.871

10.  Type B adverse drug reactions reported by an immunoallergology department.

Authors:  Maria J Costa; Maria T Herdeiro; Jorge J Polónia; Inês Ribeiro-Vaz; Cármen Botelho; Eunice Castro; Josefina Cernadas
Journal:  Pharm Pract (Granada)       Date:  2018-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.